Seneca Therapeutics, Inc (STI)
Seneca Therapeutics product - SVV-001 - is an extremely versatile virus able to make resistant tumors susceptible again and to deliver genes into TEM8 tumors
STI is developing SVV-001 for cancer treatment. SVV-001 can be used in combination with checkpoint inhibitors (Opdivo). SVV-001 can also be used as a viral vector to deliver genes and other drugs to TEM8 positive solid tumors. STI has also developed a SVV-001 Patient Selection Test to proactively identify patients with SVV-001 sensitive tumors. STI is also developing SVV-001 using intravenous and intratumoral dosing protocols.